Our take on the latest news and views on data.

Relevant company news, articles, podcasts, and blog posts.

Recent Posts

Industry Trends

Clinical Trial Trends

Disease Area Trends

Recent Tweets

$BMY $TSVT FDA panel approves Bristol Myers Squibb and 2seventy bio's Abecma for earlier treatment of triple-class exposed multiple myeloma.

More Info: https://pryzm.ozmosi.com/product/21140 $XBI $IBB $XPH $PPH

U.S. FDA Oncologic Drugs Advisory Committee suggests CARVYKTI® (ciltacabtagene autoleucel) for early treatment of relapsed or refractory multiple myeloma patients.

More Info: https://pryzm.ozmosi.com/product/20124 $XBI $IBB $XPH $PPH

Using [99m]Tc-Maraciclatide imaging is consistent with detecting early-stage endometriosis during laparoscopic surgery.

More Info: https://pryzm.ozmosi.com/product/5769 $XBI $IBB $XPH $PPH

Bristol Myers gets FDA accelerated approval for Breyanzi in CAR-T class for chronic lymphocytic leukemia https://buff.ly/3TklqbH $BMY #leukemia #FDA

Load More

Get Started with OZMOSI

We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.

600 Warren Ave,
Spring Lake, NJ 07762